E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Liver metastasis from colorectal cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer of the large bowel (colon) spreading to the liver. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010029 |
E.1.2 | Term | Colorectal cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This is a multi-centre, double-blinded, randomized, placebo-controlled clinical intervention trial with acetylsalicylic acid (ASA, Trombyl) in patients undergoing liver resection for colorectal cancer liver metastasis (CRCLM). The main objective is to determine whether treatment with 160 mg ASA (Trombyl) once daily for 3 years can improve Disease Free Survival (DFS) in patients treated with resection for CRCLM, compared with placebo. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to determine the effect of Trombyl on Time to Recurrence (TTR), Overall Survival (OS), and QoL in CRCLM patients, compared with placebo. Determine if ASA can improve DFS and OS in patients with mutations in PIK3CA. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All subjects undergoing liver resection for CRCLM as a part of a curative intent may be included in the study if • They meet one of the following criteria: o First time CRCLM (synchronous or metachronous) o Recurrence of CRCLM (not previously included in this trial) • Histologically verified free resection margins (R0 resection or R1 (<1mm margin + chemotherapy)) • Must be ambulatory with a performance status ECOG 0-2 • Must be at least 18 years of age • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations. |
|
E.4 | Principal exclusion criteria |
Concomitant use of ASA or other anticoagulants or platelet inhibitors such as warfarin or klopidogrel • Ongoing regular use of corticosteroids, NSAIDs • Inherited or acquired coagulopathy (hemophilia) • Severe heart failure (classified as NYHA class >III) or kidney failure • CRCLM treated with radiofrequency or microwave ablation technique • Pregnancy or breastfeeding (negative pregnancy test will be required when indicated) • Childbearing potential without proper contraceptive measures such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to avoid pregnancy for the entire study period • Liver cirrhosis with a Child-Pugh score >B7 • Contraindication listed on the Summary of Product Characteristics (SmPC) of Trombyl: • Hypersensitivity/allergies to ASA • Previous severe gastrointestinal haemorrage/peptic ulcer due to ASA/NSAID • Active peptic ulcer • Hemophilia • Need to use medications contraindicated according to SmPC of Trombyl from Medicines Agency |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time from randomisation to disease recurrence (by CT scan or MRI) or death by any cause (DFS). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
All included patients will be monitored with CT-scan of the chest and abdomen every 4 months for 1 year and further every 6 months till end of study period ( total three years). This is in-line with the Norwegian National Guidelines for follow-up of patients operated for CRC liver metastases. |
|
E.5.2 | Secondary end point(s) |
Efficacy endpoints - Time from randomisation to disease recurrence (TTR) - Time from randomisation to death by any cause (OS) HRQOL outcome measures: - SF36 - EQ-5D health surveys |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All included patients will be monitored with CT-scan of the chest and abdomen every 4 months for 1 year and further every 6 months till end of study period ( total three years). Health-related QoL surveys (SF36 and EQ-D5) will be filled out by the patient at every clinical control, which is every 4 months for 1 year and further every 6 months till end of study period ( total three years). Time of death will be registered until end of study period (total three years) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |